Allogeneic mesenchymal bone marrow cells: Completed Phase I/IIa enrollment

Stemedica completed enrollment of 36 patients in an open-label, U.S. Phase I/IIa trial evaluating single IV doses of 0.5, 1 and 1.5 million allogeneic mesenchymal bone marrow cells. ...